Clinical Trial · NCT06782412

Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types

Overview

The aim of the project is to demonstrate superior detection ratio of [18F]AlF-FAPI-74 PET/CT compared to [18F]FDG PET/CT or conventional imaging in treatment-naïve, newly diagnosed patients with oesophagogastric adenocarcinoma (clinical T1-4N0-3M0) and pancreatic ductal adenocarcinoma (clinical T1-4N0-2M0-1) and describe the clinical utility of [18F]AlF-FAPI-74 PET/CT in oncological patients with a clinically challenging situation.

Sponsor

KU Leuven

Phase

Phase 2/3

Contacts

Karen Gerboes (Professor)

hiruz@uzgent.be

+32 9 332 05 30

Christopher Deroose (Professor)

deroose@azleuven.be

+32 1 643 37 15

ClinicalTrials.gov

NCT06782412

Drug / Compound

[18F]AlF-FAPI-74

Isotope(s):

Target(s):

[18F]FDG

Isotope(s):

Target(s):

Glucose Transport